NCT01234766View on ClinicalTrials.gov

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2021

Study Completion Date

April 1, 2021

Conditions
Lymphoma, Follicular
Interventions
DRUG

Bendamustine

90mg/m2, IV - Days 1 and 2 of every cycle

DRUG

Rituximab

375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle

RADIATION

Y-90 ibritumomab

0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes

Trial Locations (4)

27710

Duke University Medical Center, Durham

04074

Maine Center for Cancer Medicine, Scarborough

03756

Dartmouth-Hitchcock Medical Center, Lebanon

02903

Rhode Island Hospital, Providence

Sponsors

Collaborators (1)

Cephalon
All Listed Sponsors
collaborator

Cephalon

INDUSTRY

collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT01234766 - Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma | Biotech Hunter | Biotech Hunter